ALLO: Allogene Therapeutics, Inc. Stock

by  •  • Comments Off on ALLO: Allogene Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 570.31
Enterprise Value ($M) 519.07
Book Value ($M) 463.75
Book Value / Share 2.21
Price / Book 1.23
NCAV ($M) 179.04
NCAV / Share 0.85
Price / NCAV 3.19

Profitability (mra)
Return on Invested Capital (ROIC) -0.51
Return on Assets (ROA) -0.40
Return on Equity (ROE) -0.49

Liquidity (mrq)
Quick Ratio 9.35
Current Ratio 9.35

Balance Sheet (mrq) ($M)
Current Assets 304.42
Assets 589.12
Liabilities 125.37
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
3 days ago 13G/A Vanguard Group Inc 3.98 0.00
7 days ago 13G/A BlackRock, Inc. 8.50 0.00
02-14 13G/A Belldegrun Arie 5.80 11.71
02-14 13G/A Chang David D 5.80 18.23
02-09 13G/A Fmr Llc 15.00 1.30
01-29 13G/A BlackRock Inc. 5.90 12.55
01-23 13G/A State Street Corp 1.44 -73.52
2023-10-25 13D/A Pfizer Inc 13.14 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REP
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT P
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT
2024-03-14 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A _______________(Amendment No. 1)__________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal ye
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-14 709,361 2,375,168 29.87
2024-11-13 514,918 1,602,820 32.13
2024-11-12 592,361 1,923,781 30.79
2024-11-11 722,193 2,625,559 27.51

(click for more detail)

Similar Companies
ALEC – Alector, Inc. ALKS – Alkermes plc
ALLK – Allakos Inc. ALNY – Alnylam Pharmaceuticals, Inc.
ALXO – ALX Oncology Holdings Inc.


Financial data and stock pages provided by
Fintel.io